Abstract Library

#4312 Developing innovative, genetically modified, proliferation-regulated patient-derived models representing human well-differentiated GEP-NETs for drug screening

Introduction: The slow-growing nature of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) has limited the development of clinically relevant models, hindering the discovery in the field.

Conference:

Presenting Author: Zuo X

Authors: Zuo X, Liu Y, Maxwell J, Halperin D, Dasari A,

Keywords: Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumour, Patient-Derived Cancer Model, Doxycycline-Controlled Genetic Modification, Drug Screening,

#4092 Liver transplantation for neuroendocrine tumor liver metastases: UK and Ireland’s pioneering pilot programme

Introduction: The incidence of neuroendocrine tumours (NETs) continues to rise. Liver metastases (LM) are commonly present at diagnosis. Liver transplantation (LT) has become an applicable treatment for a subset of these patients.

Conference:

Presenting Author: Rehman Z

Authors: Rehman Z, Ford S, Dasari B, Hughes S, El-Shafie M,

Keywords: metastases, transplant, liver, neuroendocrine,

#4075 A phase II study of Lenvatinib and Everolimus in advanced well-differentiated extra pancreatic neuroendocrine tumors

Introduction: Data suggest that combined inhibition of VEGF and FGF is an effective antiangiogenic strategy and that concomitant inhibition of the mTOR pathway may be further synergistic.

Conference:

Presenting Author: Dasari A

Authors: Dasari A, Qiao W, Halperin D, Stanietzky N, Surabhi V,

Keywords: Extrapancreatic NET, Lenvatinib, Everolimus, Phase II,

#3955 Development of clinically representative patient-derived organoid models for diverse G1/G2 gastroenteropancreatic neuroendocrine tumors

Introduction: While gastroenteropancreatic neuroendocrine tumors (GEP-NETs) grow slowly, they are incurable when reaching advanced stages. The characteristic slow growth of GEP-NETs results in the scarcity of clinically relevant models that has hindered our comprehension of GEP-NET biology and pathology, leading to limited progress in systemic therapies of GEP-NET treatment.

Conference:

Presenting Author:

Authors: Zuo X, Liu Y, Maxwelll J, Halperin D, Dasari A,

Keywords: gastroenteropancreatic neuroendocrine tumors, patient-derived organoids, Dox-controlled genetic modifications, characterization,

#3620 Real-world SEER-Medicare data analysis of the evolution of tumor characteristics, first-line therapies and overall survival (OS) in patients with neuroendocrine tumors (NETs)

Introduction: Recent data on NET therapy utilization and impact in real-world practice are scarce.

Conference:

Presenting Author:

Authors: Schneider M, Sinha A, Dasari A, Chan J, Stoffels A,

Keywords: neuroendocrine tumor, NET characteristics, first-line therapy, treatment evolution, treatment patterns, overall survival,